GILD - GILEAD SCIENCES, INC.
114.43
-2.780 -2.429%
Share volume: 11,459,627
Last Updated: 03-11-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.00%
PREVIOUS CLOSE
CHG
CHG%
$117.21
-2.78
-0.02%
Fundamental analysis
49%
Profitability
32%
Dept financing
34%
Liquidity
9%
Performance
81%
Performance
5 Days
-2.54%
1 Month
10.76%
3 Months
23.87%
6 Months
37.60%
1 Year
52.41%
2 Year
43.92%
Key data
Stock price
$114.43
DAY RANGE
$113.92 - $116.98
52 WEEK RANGE
$62.07 - $119.96
52 WEEK CHANGE
$50.68
DIVIDEND
$0.77
EX-DIVIDEND DATE
06-14-2024
NEXT EARNINGS DATE
N/A
Company detail
CEO: Daniel P. O'Day
Region: US
Website: gilead.com
Employees: 17,000
IPO year: 1992
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Region: US
Website: gilead.com
Employees: 17,000
IPO year: 1992
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Gilead Sciences discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, and Atripla products for the treatment of HIV/AIDS.
Recent news